RFA-CA-23-038: Integrating Health Disparities into Immuno-Oncology (HDIO) (P20 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $250,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on June 30, 2023.
From the official notice on Grants.gov, last changed April 27, 2023. Checked November 7, 2026.
- Award ceiling$250,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeP20
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$244,657
- Typical project length2.5 years
- P20, Exploratory Grant. Planning or building a research center or program. Other open P20 notices.
Projects funded under RFA-CA-23-038 were run by National Cancer Institute (NCI, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-23-038 in the NIH Guide.
Key dates
| Posted | April 27, 2023 |
|---|---|
| Deadline | June 30, 2023 |
| Archived by Grants.gov | August 5, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $244,657; it allows up to $250,000 per award.
- Most of the program's money (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The scientific objectives of this P20 FOA are to support planning and feasibility studies to integrate cancer health disparities into immuno-oncology research studies. The P20 project will enable complementary, multi-disciplinary research teams to address inter-disciplinary research to integrate cancer health disparities into immuno-oncology research. It is anticipated these feasibility or pilot studies will support the exploration of novel or high-risk research hypotheses.
Funded under RFA-CA-23-038 so far
NIH funded 4 projects under RFA-CA-23-038 in fiscal 2024 to 2025, at 4 institutions. The median yearly award was $244,657.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Addressing cancer disparities in Nigeria through Immuno-oncology Research – The NOLA Program | Sloan-Kettering Inst Can Research | 2025 | $87,066 |
| The role of immunosuppression in the tumor microenvironment in Hispanic/Latino patients with breast cancer | University of Southern California | 2025 | $267,770 |
| Project 1 | Wayne State University | 2025 | $283,705 |
| Admin Core | University of California, San Francisco | 2025 | $277,529 |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-23-038 still open?
No. It closed on June 30, 2023.
Who can apply for Integrating Health Disparities into Immuno-Oncology (HDIO) (P20 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Integrating Health Disparities into Immuno-Oncology (HDIO) (P20 Clinical Trial Not Allowed)?
Closed June 30, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $250,000 each.
Who has been funded under RFA-CA-23-038?
NIH RePORTER lists 4 projects funded under RFA-CA-23-038 in fiscal 2024 to 2025, at 4 institutions. The most were at Sloan-Kettering Inst Can Research, University of Southern California, Wayne State University.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Community-Partnered Nursing Research Centers (P20 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)